Dr. Brain Completed A Few Million Dollars in Series A Financing

Dr. Brain just completed a few million dollars in Series A financing, this round of financing was led by Beilu Pharmaceuticals Company. The funds will be used for production line improvement and product development.

Dr. Brain was founded in 2017, it is an artificial intelligence diagnosis and analysis platform focusing on central nervous system diseases. Based on the company's own brain image database, it uses cloud computing and other core technologies to accurately assess changes in the whole brain structure and to diagnosis central nervous system diseases. At present, the platform has developed products for Alzheimer's disease, Parkinson's disease, stroke, cerebral hemorrhage, brain tumors and other diseases.

Central nervous system diseases and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease have accounted for more than 65% of this national deaths. From 2005 to 2016, the number of deaths from Alzheimer's disease has increased by 57.8%, accounting for 4.9% of the total death toll. As the aging of the population continues to increase, there is still much room for improvement in the prevention and treatment of central nervous system diseases.

Dr. Brain's platform has been deployed in nearly 100 well-known hospitals across China, providing AI-assisted diagnostic tools and analysis platforms for medical institutions, significantly improving the accuracy and efficiency of clinical diagnosis.

Beijing BeiLu Pharmaceutical was established in September 1992, mainly engaged in pharmaceutical product development, production and sales.